Antibodies to watch in 2015

mAbs

Volumn 7, Issue 1, 2015, Pages 1-8

  Reichert, Janice M ^a  

^a Reichert Biotechnology Consulting LLC   (United States)

Author keywords

Biosimilar antibodies; Cancer; Clinical studies; European Medicines Agency; Food and Drug Administration; Immune mediated disorders; Monoclonal antibodies

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; BIMAGRUMAB; BLINATUMOMAB; BOCOCIZUMAB; BRODALUMAB; DINUTUXIMAB; DUPILUMAB; EPRATUZUMAB; EVOLOCUMAB; GEVOKIZUMAB; GUSELKUMAB; IXEKIZUMAB; MEPOLIZUMAB; NIVOLUMAB; OBILTOXAXIMAB; OCRELIZUMAB; PEMBROLIZUMAB; RACOTUMOMAB; RAMUCIRUMAB; RECOMBINANT ANTIBODY; RESLIZUMAB; ROMOSOZUMAB; SARILUMAB; SECUKINUMAB; SILTUXIMAB; SIRUKUMAB; TILDRAKIZUMAB; UNINDEXED DRUG; VEDOLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBIOTIC THERAPY; ASTHMA; ATOPIC DERMATITIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; COLORECTAL CARCINOMA; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LONG TERM CARE; MAINTENANCE THERAPY; MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PSORIASIS VULGARIS; PYODERMA GANGRENOSUM; REVIEW; SQUAMOUS CELL LUNG CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; UNITED STATES;

EID: 84921345093     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2015.988944     Document Type: Review

References (27)

1. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014; pii: S0140-6736(14)61374-X; PMID:25282520; http://dx.doi.org/10.1016/S0140-6736(14)61374-X
2. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014; pii: S0140-6736(14)61399-4; PMID:25282519; http://dx.doi.org/10.1016/S0140-6736(14)61399-4
3. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371(13):1198-207; PMID:25199059; http://dx.doi.org/10.1056/NEJMoa1403290
4. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371(13):1189-97; PMID:25199060; http://dx.doi.org/10.1056/NEJMoa1403291
5. Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. MAbs. 2013; 5:801-9. PMID:23924804
6. Thatcher N, Hirsch FR, Szczesna A, Ciuleanu T-E, Szafranski W, Dediu M, Ramlau R, Galiulin R, Bálint B, Losonczy G, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol 2014; 32:5s; (suppl; abstr 8008). http://meetinglibrary.asco.org/content/125543-144
7. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014; 176(1):55-61; PMID:25037695; http://dx.doi.org/10.1016/j.ijcard.2014.06.049
8. Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F; et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2014;34(4):606-18; PMID:24298022; http://dx.doi.org/10.1128/MCB.01307-13
9. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang E, Plowchalk D, Sweeney K, Kaila N, Vincent J, Bays H. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT:01592240). J Am Coll Cardiol 2014; 63(12-S); http://dx.doi.org/10.1016/S0735-1097(14)61374-7
10. Beck LA, Thac¸i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371 (2):130-9; PMID:25006719; http://dx.doi.org/10.1056/NEJMoa1314768
11. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014; 73(9):1616-25; PMID:24699939; http://dx.doi.org/10.1136/annrheumdis-2013-205137
12. Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014; 73(9):1626-34; PMID:24297381; http://dx.doi.org/10.1136/annrheumdis-2013-204405
13. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014; 133(4):1032-40; PMID:24679469; http://dx.doi.org/10.1016/j.jaci.2014.01.025
14. Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, Kelley L, Kilgallen B, Wegener WA, Goldenberg DM. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014; 53(3):502-11; PMID:24273022
15. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370(5):412-20; PMID:24382002; http://dx.doi.org/10.1056/NEJMoa1305224
16. Vázquez AM, Hernández AM, Macías A, Montero E, Gómez DE, Alonso DF, Gabri MR, Gómez RE. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol 2012; 2:150; PMID:23110257
17. Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, Viada CE, Mendoza IC, Guerra PP, García E, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014; 20(14):3660-71; PMID:24788102; http://dx.doi.org/10.1158/1078-0432.CCR-13-1674
18. Gold DV, Newsome G, Liu D, Goldenberg DM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer 2013; 12(1):143; PMID:24257318
19. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Urẽna S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10):1613-20; PMID:23687260; http://dx.doi.org/10.1136/annrheumdis-2012-203090
20. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72(10):1605-12; PMID:23687259; http://dx.doi.org/10.1136/annrheumdis-2012-203091
21. Reichert JM. Antibodies to watch in 2014: Mid-year update. MAbs 2014; 6:799-802; PMID:24846335; http://dx.doi.org/10.4161/mabs.29282
22. Reichert JM. Antibodies to watch in 2014. MAbs 2014; 6:5-14; PMID:24284914; http://dx.doi.org/10.4161/mabs.27333
23. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 2013; 5:513-7; PMID:23727858; http://dx.doi.org/10.4161/mabs.24990
24. Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013; 5:1-4; PMID:23254906; http://dx.doi.org/10.4161/mabs.22976
25. Reichert JM. Which are the antibodies to watch in 2012? MAbs 2012; 4:1-3; PMID:22327425; http://dx.doi.org/10.4161/mabs.4.1.18719
26. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76-99; PMID:21051951
27. Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84-100; PMID:20065640